Sino Biopharmaceutical (HKG:1177) said its fourth-generation EGFR inhibitor TQB3002's application for the investigational new drug (IND) was approved by the US FDA with Phase I clinical trials to begin soon.
TQB3002 is a fourth-generation oral small-molecule EGFR inhibitor, which is used to treat cancers, including non-small cell lung cancer, according to a Thursday filing with the Hong Kong bourse
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.